Company News

August 05

Gmax Biopharm Appointed Vice Presidents

Gmax Biopharm LLC. Recently appointed Mr. Alex Hie Lin Wong Vice Presidents to strengthen Gmax Biopharm in clinical development, aiming to deliver the innovative therapeutics to the global patients in rapid and stable fashion.

June 14

Strong Team - Four Senior Experts Join Gmax Biopharm

They will provide Gmax with scientific and strategic advisory on R&D, global multi-center clinical trials, international business development and IPO, etc.


Gmax initiates the multi-region, multi-center clinical trial of Getago

Gmax initiated the multi-region, multi-center clinical trial of Getagozumab in pulmonary arterial hypertension (PAH) patients.


Gmax long-acting GLP-1R agonist has been approved by the China Human G

Glutazumab (GMA102) has been approved for the IND in August 2018, in China. Gmax has initiated a multi-center, randomized, double-blinded, placebo controlled clinical trial in China.

August 11

Gmax Announces Approval of Glutazumab for Investigational New Drug (IN

Glutazumab (GMA102) has been approved by Center for Drug Evaluation (CDE, CFDA) for the IND of type 2 diabetes (T2D).

18 Records 1234